Biogen poached Novartis vet Alaimo as SVP of U.S. therapeutic operations, Aeterna CEO Dodd left, and Merrimack hired a former C4 exec as its CBO.

Researchers have uncovered clues into how a genetic variant raises the risk of migraines, coronary artery disease and other related disorders.

In this week's EuroBiotech Report, AstraZeneca is rocked by Mystic data, GSK culls its pipeline, Bayer posts weak cancer data and more.

The Novartis-partnered p53 gene-targeting siRNA cut the rate of acute kidney injury in patients following cardiac surgery.

PARP inhibitor Lynparza may be able to kill cancer cells that don’t have BRCA mutations—provided it’s paired with a helper compound.

BeiGene is adding Medidata’s electronic patient-reported outcome solution to oncology clinical studies.

Get Wednesday's shot of biopharma news of note.

University of California starts its fightback against rival Broad Institute in their dispute over intellectual property for CRISPR-Cas9.

The decision follows a review that foresaw bleak prospects for the program and little reason to invest in its development.